Hearing may be End of Road for Breast Cancer Drug Avastin


June 29, 2011

USA Today

The best-selling cancer drug in the world comes under federal scrutiny once again this week, as drugmaker Roche makes a last-ditch effort to keep Avastin approved for breast cancer, despite the government's opinion that it is ineffective against the disease. The two-day meeting at the Food and Drug Administration is unprecedented since the agency has already ruled against the drug, saying it neither extends nor improves life for breast cancer patients. Roche has taken the rare step of challenging government regulators. Experts say the fact that the agency granted another hearing on the issue is testament to the difficulty of withdrawing approval of a cancer therapy... Read More